We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
HASO | Hastings Technology Metals Limited | 0.035 | 0.019 | 118.75% | 4,631 | 2 |
ZEUO | Zeus Resources Limited | 0.002 | 0.001 | 100.00% | 50,000 | 1 |
IPTOB | Impact Minerals Ltd | 0.002 | 0.001 | 100.00% | 500,000 | 1 |
RC1O | Redcastle Resources Ltd | 0.002 | 0.001 | 100.00% | 5,000,000 | 1 |
GTI | Gratifii Limited | 0.011 | 0.004 | 57.14% | 11,218,173 | 20 |
RCR | Rincon Resources Limited | 0.15 | 0.054 | 56.25% | 39,665,132 | 959 |
PL3O | Patagonia Lithium Ltd | 0.017 | 0.006 | 54.55% | 330,000 | 3 |
SRNOD | Surefire Resources NL | 0.003 | 0.001 | 50.00% | 167,333 | 1 |
BUYO | Bounty Oil & Gas | 0.003 | 0.001 | 50.00% | 1,183,332 | 3 |
ADG | Adelong Gold Limited | 0.004 | 0.001 | 33.33% | 116,333 | 2 |
EDE | Eden Innovations Ltd | 0.002 | 0.0005 | 33.33% | 1,734,954 | 8 |
CUPERTINO, Calif., April 30, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024 to take place June 5-8, 2024 in Milan, Italy. The presentation will discuss data from the Company's Phase 2b AHFIRM trial, which evaluated the safety and efficacy of larsucosterol as a treatment for patients with severe alcohol-associated hepatitis (AH).
NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that effective May 1, 2024, the Company’s PainShield product will be included in the U.S. Department of Veteran Affairs’ (“VA”) Federal Supply Schedule (“FSS”), a program that supports the healthcare acquisition needs of the VA and other government agencies.
WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on May 1, 2024 the Company granted inducement awards to purchase up to 100,600 shares of common stock to six new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 63,133.88 | 4,012.68 | 6.79% | 1.24T | 5,590,088,847 |
ETH | Ethereum | 3,112.41 | 125.33 | 4.20% | 373.52B | 2,239,825,486 |
USDT | Tether USD | 1.00 | 0.00002 | 0.00% | 97.84B | 274,273,528 |
BNB | Binance Coin | 588.28 | 27.69 | 4.94% | 92.85B | 263,915,332 |
SOL | Solana | 144.42 | 6.75 | 4.90% | 63.37B | 1,227,123,534 |
STETH | stETH | 3,107.34 | 127.72 | 4.29% | 30.38B | 28,703,085 |
XRP | Ripple | 0.5326 | 0.0146 | 2.82% | 29.03B | 332,128,428 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 1,069,685,306 |
DOGE | Dogecoin | 0.14762 | 0.01555 | 11.77% | 20.95B | 392,863,194 |
TONCOIN | Wrapped TON Coin | 5.70 | 0.55029 | 10.69% | 20.01B | 145,157,769 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions